Search Results - "Ha, Eunsin"

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models by Yeom, Dong-Hoon, Lee, Yo-Seob, Ryu, Ilhwan, Lee, Sunju, Sung, Byungje, Lee, Han-Byul, Kim, Dongin, Ahn, Jin-Hyung, Ha, Eunsin, Choi, Yong-Soo, Lee, Sang Hoon, You, Weon-Kyoo

“…Delta-like-ligand 4 (DLL4) is a promising target to augment the effects of VEGF inhibitors. A simultaneous blockade of VEGF/VEGFR and DLL4/Notch signaling…”
Get full text

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer by Kim, Da-Hyun, Lee, Seul, Kang, Hyeok Gu, Park, Hyun-Woo, Lee, Han-Woong, Kim, Dongin, Yoem, Dong-Hoon, Ahn, Jin-Hyung, Ha, Eunsin, You, Weon-Kyoo, Lee, Sang Hoon, Kim, Seok-Jun, Chun, Kyung-Hee

“…Notch signaling has been identified as a critical pathway in gastric cancer (GC) progression and metastasis, and inhibition of Delta-like ligand 4 (DLL4), a…”
Get full text

Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma by Kim, KyeongJin, Kim, Kook Hwan, Ha, Eunsin, Park, Jin Young, Sakamoto, Naoya, Cheong, JaeHun

“…Steatosis is an established risk factor for disease progression in cases of chronic hepatitis C. Recently it was demonstrated that Hepatitis C virus (HCV) core…”
Get full text

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer by Kim, Da-Hyun, Lee, Seul, Kang, Hyeok Gu, Park, Hyun-Woo, Lee, Han-Woong, Kim, Dongin, Yoem, Dong-Hoon, Ahn, Jin-Hyung, Ha, Eunsin, You, Weon-Kyoo, Lee, Sang Hoon, Kim, Seok-Jun, Chun, Kyung-Hee

“…Notch signaling has been identified as a critical pathway in gastric cancer (GC) progression and metastasis, and inhibition of Delta-like ligand 4 (DLL4), a…”
Get full text

CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study by Oh, Do-Youn, Park, Joon Oh, Kim, Jin Won, Kim, Kyu-Pyo, Yoon, Jeesun, Kim, Tae-Yong, Kim, Seung Tae, Park, Young Suk, Lee, Jeeyun, Kim, Ji-Won, Lee, Keun-Wook, Ryoo, Baek-Yeol, Yoo, Changhoon, Hyun, BokJin, Son, HyunJoo, Kim, SunYoung, Lee, SangMi, Park, Jooyeon, Ha, Eunsin

“…540 Background: CTX-009 is a novel bispecific antibody that simultaneously inhibits Delta-like ligand 4/Notch-1 (DLL4) and VEGF A, two signaling molecules…”
Get full text

Abstract P02-03: Phase Ia/Ib dose-escalation study of ABL001 (CTX-009, bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors by Lee, Jeeyun, Kim, SeungTae, Hong, JungYong, Park, YoungSuk, Park, JoonOh, Kang, WonKi, Lee, Keun-Wook, Kim, Jin Won, Kim, Ji-Won, Kim, Se Hyun, Ha, Eunsin, Lee, Sangmi, Kim, JongRan, You, Weon-Kyoo

“…Abstract VEGF blockade is a validated therapeutic approach and anti-VEGF antibodies are established components of several standard regimens for various…”
Get full text

Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer by Lee, Jeeyun, Kim, Seung, Lee, Su Jin, Park, Se Hoon, Park, Joon Oh, Ha, Eunsin, Park, Doo-Hong, Park, Neunggyu, Kim, Hoon-Kyo, Lee, Sang Hoon, You, Weon-Kyoo, Lim, Ho Yeong, Park, Young Suk, Kang, Won Ki

“…Abstract only 3023 Background: Antiangiogenic therapy has been a successful clinical strategy for the treatment of various cancer types. To date, all approved…”
Get full text